A qui­et Czech biotech bags $315M to dri­ve its blos­som­ing can­cer pipeline through the clin­ic

In the rather in­su­lar world of biotech, most in­no­va­tion in­evitably comes from a clus­ter of R&D hubs — Cam­bridge, San Fran­cis­co, etc. But some­times suc­cess sto­ries sprout from rocky soil, which is most cer­tain­ly the case with Prague-based So­tio Biotech and its sud­den­ly jam-packed pipeline of can­cer drugs.

Af­ter years in qui­et de­vel­op­ment, So­tio now has $315 mil­lion in new funds to play with from par­ent com­pa­ny PPF Group, an in­vest­ment group found­ed in the Czech Re­pub­lic, as the biotech looks to ad­vance its grow­ing pipeline through ear­ly- and mid-stage tri­als.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER